Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lexeo Therapeutics, Inc. (LXEO – Research Report), RAPT Therapeutics (RAPT – Research Report) and Hookipa Pharma (HOOK – Research Report).
Lexeo Therapeutics, Inc. (LXEO)
Leerink Partners analyst Mani Foroohar reiterated a Buy rating on Lexeo Therapeutics, Inc. on May 9 and set a price target of $19.00. The company’s shares closed last Monday at $13.56.
According to TipRanks.com, Foroohar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Lexeo Therapeutics, Inc. is a Strong Buy with an average price target of $21.33, representing a 62.5% upside. In a report issued on May 9, RBC Capital also maintained a Buy rating on the stock with a $24.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
RAPT Therapeutics (RAPT)
In a report issued on May 9, Thomas Smith from Leerink Partners reiterated a Hold rating on RAPT Therapeutics, with a price target of $10.00. The company’s shares closed last Monday at $4.40, close to its 52-week low of $4.18.
According to TipRanks.com, Smith is a top 100 analyst with an average return of
RAPT Therapeutics has an analyst consensus of Hold, with a price target consensus of $13.80, representing a 218.7% upside. In a report issued on May 9, Guggenheim also downgraded the stock to Hold.
Hookipa Pharma (HOOK)
Leerink Partners analyst Andrew Berens maintained a Buy rating on Hookipa Pharma on May 9 and set a price target of $4.00. The company’s shares closed last Monday at $0.77.
According to TipRanks.com, Berens is a 1-star analyst with an average return of
Hookipa Pharma has an analyst consensus of Strong Buy, with a price target consensus of $4.75, representing a 527.1% upside. In a report issued on April 26, H.C. Wainwright also maintained a Buy rating on the stock with a $5.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LXEO:
- Lexeo sees cash, equivalents sufficient to fund operations into 2027
- Lexeo Therapeutics reports Q1 EPS (77c), consensus (77c)
- Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
- Lexeo Therapeutics to Participate in Upcoming Investor Conferences
- Bernard Davitian to Exit Board of Lexeo Therapeutics
